Abstract
The Epidermal Growth Factor (EGF) Receptor (EGFR) is a receptor tyrosine kinase that when deregulated can drive tumor growth and can also contribute to drug resistance. Upon binding its ligand EGF, EGFR triggers the activation of many signaling pathways including phosphatidylinpositol‐3‐kinase (PI3K)/Akt, Ras‐Erk, signal transducer and activator of transcription (STAT), and phospholipase C γ1 (PLCγ1). EGFR may also control DNA repair mechanisms, although this phenomenon this remains poorly understood. Control of DNA repair by EGFR may be particularly relevant in the context of action of and resistance to anti‐cancer drugs that cause DNA damage (e.g. cisplatin). We examined how acute activation (10–30 min) of EGFR by ligand stimulation regulates DNA damage and repair responses induced by chronic (16 h) cisplatin treatment. To do so, we examined various markers of DNA damage and repair such as γH2AX and 53BP1. We observed that as little as 10 min of EGF stimulation is sufficient to elicit remodelling of DNA damage and repair markers such as γH2AX in chronic cisplatin‐treated cells. This indicates that acute EGFR activation triggers signaling pathway(s) that control the DNA damage response and/or DNA repair. Using these methods, we dissected the contribution of various EGFR signaling pathways and membrane traffic phenomena to this EGFR‐dependent control of DNA repair. This work may reveal new ways to enhance the efficacy of existing chemotherapies such as cisplatin for cancer treatment.Support or Funding InformationThis work was supported by a Project Grant and a New Investigator Salary Award from the Canadian Institutes of Health Research (CIHR) to C.N.AThis abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have